Bioabsorbable Stents
Abbott closes 3 clinical trials for disappearing drug-eluting coronary stent
Terumo inks deal for Arterial Remodeling’s bioresorbable stent
Arterial Remodeling Technologies said it inked a deal with Terumo Corp. (TYO:4543) for its bioresorbable drug-eluting coronary stent that includes an exclusive buyout option.
Abbott kicks off a Japanese trial for its “dissolving” vascular scaffold
Boston Scientific legal update: Ups and downs in tussles with Iraq, OrbusNeich and the feds
Boston Scientific (NYSE:BSX) is no stranger to the court room, and its latest quarterly release is a testament to the company’s legal tenacity.
Elixir Medical wins CE Mark for bioresorbable DESolve stent
Elixir Medical’s DESolve Novolimus eluting bioresorbable coronary scaffold system won European CE Mark approval, the privately held Sunnyvale, Calif.-based company announced today.
DESolve is designed to degrade in about 1 year, returning the patients’ coronary vessel to its normal de novo state.
Elixir plans to initiate commercial sales of DESolve in a broad range of sizes in select international markets later this year, according to a press announcement.
Ad-Tech brain implant recall gets FDA’s highest-risk status | MassDevice.com On Call
MASSDEVICE ON CALL — Federal healthcare regulators gave Ad-Tech Medical Instrument Corp.’s wide-reaching brain implant recall Class I status, the highest-risk category for medical device recalls.
Late last year the Wisconsin-based medical device maker recalled its Macro Micro Subdural Electrodes over concerns that the implanted devices could cause damage to the brain.
Mixed review for Biotronik’s absorbable stent
German medical device maker Biotronik touted early findings from a 1st-in-man study of its Dreams absorbable drug-eluting stent, with researchers reporting a mixed bag of findings for the device.
The Dreams stent proved safe at 1 year following the procedure, but wasn’t up to par with some rival devices, researchers noted.
Stents: Abbott starts Absorb clinical trial
Boston Scientific’s Synergy stent lands CE Mark
Boston Scientific (NYSE:BSX) said it won CE Mark approval for its Synergy drug-eluting stent, with a bioabsorbable coating designed to deliver the drug everolimus over the 3 months it takes to dissolve.
TCT 2012: Drug-eluting and semi-resorbable stents hold their own
Stent makers came out in force for the Transcatheter Cardiovascular Therapeutics meeting in Miami this week, touting results of clinical studies of next-generation drug-eluting stents and new designs with bioresorbable polymers.